CINJ 050604: A Phase 1 Study of the Safety and Efficacy of GC1008: A Human Anti Transforming Growth Factor-beta (TGFb) Monoclonal Antibody in Patients with Advanced Renal Cell Carcinoma and Malignant Melanoma (Genzyme Protocol no. GC100800305).

Trial Profile

CINJ 050604: A Phase 1 Study of the Safety and Efficacy of GC1008: A Human Anti Transforming Growth Factor-beta (TGFb) Monoclonal Antibody in Patients with Advanced Renal Cell Carcinoma and Malignant Melanoma (Genzyme Protocol no. GC100800305).

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs Fresolimumab (Primary)
  • Indications Malignant melanoma; Renal cell carcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (parent trial: NCT00356460).
    • 24 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (parent trial: NCT00356460).
    • 24 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (parent trial: NCT00356460).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top